ShortStop-HER2: 12 Months vs. 6 Months of HER2-targeted Medications for People With HER2+ Breast Cancer Who Had a Pathologic Complete Response After Chemotherapy Plus Trastuzumab

Clinical trial NCT06876714 · RECRUITING

Trial details

NCT number: NCT06876714
Sponsor: Alliance for Clinical Trials in Oncology
Status: RECRUITING
Phase: Phase 3
Study type: INTERVENTIONAL

Anatomic Stage I Breast Cancer AJCC v8 Anatomic Stage II Breast Cancer AJCC v8 Early Stage HER2+ Breast Cancer

Start date: 2025-09-17
Primary completion: 2028-03-13
Enrollment: 1524

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.